%PDF-1.4
%
33 0 obj
<>
endobj
30 0 obj
<>
endobj
86 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-08-05T16:36:12Z
2024-03-28T23:35:06-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T23:35:06-07:00
application/pdf
Heather
2004-726.aug
uuid:8f6ba21e-1dd2-11b2-0a00-b509275dc400
uuid:8f6ba221-1dd2-11b2-0a00-810000000000
endstream
endobj
19 0 obj
<>
endobj
20 0 obj
<>
endobj
34 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
104 0 obj
[108 0 R]
endobj
105 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 73.368 737.5293 Tm
(bowel disease, a prospective population-based study \(the IBSEN)Tj
0 -1.25 TD
(study\). Rheumatology Oxford 2001;40:1256-61.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (Gabriel SE. Classification of rheumatic diseases. In: Hochber)17.7 (g MC,)]TJ
2.175 -1.25 Td
[(Silman )54.8 (AJ, Smolen JS, )17.7 (W)79.7 (einblatt ME, )17.7 (W)79.7 (eisman MH, editors.)]TJ
0 Tc T*
[(Rheumatology)64.9 (. London: Mosby; 2003:9-12.)]TJ
-2.1381 -1.25 Td
[(1)36.9 (1.)-875 (W)79.8 (olfe F)79.8 (,)0.1 ( Smythe HA, )36.8 (Y)111.1 (unus MB, et al. )17.7 (The )54.8 (American College of)]TJ
2.1381 -1.25 Td
(Rheumatology 1990 criteria for the classification of fibromyalgia.)Tj
T*
[(Report of the Multicenter Criteria Committee. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1990;33:160-72.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (W)79.7 (are JE Jr)39.7 (, Sherbourne CD. )17.7 (The MOS 36-item short-form health)]TJ
2.175 -1.25 Td
(survey \(SF-36\). I. Conceptual framework and item selection. Med)Tj
0 Tc T*
(Care 1992;30:473-83.)Tj
-2.175 -1.25 Td
[(13.)-875 (W)79.8 (are JE Jr)39.8 (, Gandek B, Kosinski M, et al. )17.7 (The equivalence of SF-36)]TJ
2.175 -1.25 Td
(summary health scores estimated using standard and )Tj
-0.00011 Tc T*
(country-specific algorithms in 10 countries: results from the)Tj
0 Tc T*
[(IQOLA)-220.1 (Project. International Quality of Life )54.8 (Assessment. J Clin)]TJ
T*
[(Epidemiol 1998;51:1)36.9 (167-70.)]TJ
-2.175 -1.25 Td
[(14.)-875 (Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and)]TJ
2.175 -1.25 Td
[(reliable measure of therapeutic ef)17.8 (ficacy in the treatment of )]TJ
T*
[(inflammatory bowel disease. Canadian Crohn\222)54.9 (s Relapse Prevention)]TJ
T*
[(T)34.9 (rial Study Group. Gastroenterology 1994;106:287-96.)]TJ
-2.175 -1.25 Td
[(15.)-875 (Bernklev )17.8 (T)74 (, Moum B, Moum )17.8 (T)74 (. Quality of life in patients with)]TJ
2.175 -1.25 Td
[(inflammatory bowel disease: translation, data quality)64.9 (, scaling)]TJ
T*
[(assumptions, validity)64.9 (, reliability and sensitivity to change of the)]TJ
-0.00011 Tc T*
(Norwegian version of IBDQ. Scand J Gastroenterol )Tj
0 Tc 0 Tw T*
[(2002;37:1)36.9 (164-74.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Palm O, Moum B, Ongre )54.8 (A, Gran JT)73.9 (. Prevalence of ankylosing)]TJ
0 Tc 2.175 -1.25 Td
(spondylitis and other spondyloarthropathies among patients with)Tj
T*
(inflammatory bowel disease: a population study \(the IBSEN study\).)Tj
T*
[(J Rheumatol 2002;29:51)36.9 (1-5.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875.1 (Palm O, Moum B, Jahnsen J, Gran JT)73.9 (. Fibromyalgia and chronic)]TJ
0 Tc 2.175 -1.25 Td
(widespread pain in patients with inflammatory bowel disease: a)Tj
T*
[(cross sectional population survey)64.9 (. J Rheumatol 2001;28:590-4.)]TJ
-2.175 -1.25 Td
[(18.)-875 (Bjelle )54.9 (A, )54.9 (Allander E. Regional distribution of rheumatic complaints)]TJ
2.175 -1.25 Td
(in Sweden. Scand J Rheumatol 1981;10:9-15.)Tj
-2.175 -1.25 Td
[(19.)-875 (Jacobsson L, Lindgarde F)79.8 (, Manthorpe R. )17.7 (The commonest rheumatic)]TJ
2.175 -1.25 Td
[(complaints of over six weeks\222)-201 (duration in a twelve-month period in)]TJ
33.0625 45 Td
(a defined Swedish population. Prevalences and relationships. Scand)Tj
T*
(J Rheumatol 1989;18:353-60.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875.1 (Podolsky DK. Inflammatory bowel disease. N Engl J Med)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(2002;347:417-29.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875.1 (Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related)]TJ
0 Tc 2.175 -1.25 Td
(quality of life in the general Norwegian population assessed by the)Tj
T*
[(European Or)17.8 (ganization for Research and )17.7 (T)34.9 (reatment of Cancer Core)]TJ
-0.00011 Tc T*
(Quality-of-Life Questionnaire: the QLQ=C30 \(+ 3\). J Clin Oncol)Tj
0 Tc 0 Tw T*
[(1998;16:1)36.9 (188-96.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (T)69.7 (esta MA, Simonson DC. )54.8 (Assessment of quality-of-life outcomes.)]TJ
0 Tc 2.175 -1.25 Td
(N Engl J Med 1996;334:835-40.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(23.)-875.1 (Stucki G, Daltroy L, Katz JN, Johannesson M, Liang MH.)]TJ
0 Tc 2.175 -1.25 Td
(Interpretation of change scores in ordinal clinical scales and health)Tj
T*
(status measures: the whole may not equal the sum of the parts. )Tj
T*
[(J Clin Epidemiol 1996;49:71)36.9 (1-7.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(24.)-875.1 (Carr )54.8 (A. )54.8 (Adult measures of quality of life. )54.8 (Arthritis Care Res)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
[(2003;49:1)36.9 (13-33.)]TJ
0.0249 Tw -2.175 -1.25 Td
[(25.)-875 (Brekke M, Hjortdahl P)110.8 (, Kvien )17.7 (TK. Self-ef)17.8 (ficacy and health status in)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis: a two-year longitudinal observational study)64.9 (.)]TJ
T*
(Rheumatology Oxford 2001;40:387-392.)Tj
-2.175 -1.25 Td
[(26.)-875 (Da Costa D, Dobkin PL, Pinard L, et al. )17.7 (The role of stress in )]TJ
2.175 -1.25 Td
(functional disability among women with systemic lupus )Tj
T*
[(erythematosus: a prospective study)64.9 (. )54.8 (Arthritis Care Res 1999;)]TJ
-0.00011 Tc 0 Tw T*
[(12:1)36.8 (12-9.)]TJ
0 Tc 0.0249 Tw -2.175 -1.25 Td
[(27.)-875 (Strombeck B, Ekdahl C, Manthorpe R, )17.7 (W)39.8 (ikstrom I, Jacobsson L.)]TJ
2.175 -1.25 Td
[(Health-related quality of life in primary Sjogren\222)54.9 (s)0.1 ( syndrome,)]TJ
T*
(rheumatoid arthritis and fibromyalgia compared to normal )Tj
T*
(population data using SF-36. Scand J Rheumatol 2000;29:20-8.)Tj
-2.175 -1.25 Td
[(28.)-875 (L)54.9 (ydick EG and Epstein RS. Clinical significance of quality of life)]TJ
2.175 -1.25 Td
[(data. In: Spilker B, editor)54.9 (. Quality of life and pharmaco-economics)]TJ
T*
(in clinical trials, second edition. 1996:)Tj
-0.00011 Tc -2.175 -1.25 Td
[(29.)-875.1 (Juniper EF)79.7 (, Guyatt GH, )17.7 (W)39.7 (illan )54.8 (A, Grif)17.7 (fith LE. Determining a )]TJ
0 Tc 2.175 -1.25 Td
(minimal important change in a disease-specific quality of life )Tj
T*
(questionnaire. J Clin Epidemiol 1994;47:81-7.)Tj
ET
/CS0 CS 0 0 0 1 SCN
52.97 77 m
557.97 77 l
S
0 0 0 0 scn
493.79 69.86 64.18 -15.66 re
f*
BT
0 0 0 1 scn
/TT1 1 Tf
0 Tw 8 0 0 8 540.968 56.9344 Tm
(1759)Tj
ET
0 0 0 0 scn
53.03 71 203 -16.64 re
f*
BT
0 0 0 1 scn
/TT1 1 Tf
0.02499 Tw 8 0 0 8 54.032 57.0971 Tm
(Palm, et al: Joint pain in IBD)Tj
ET
0 0 0 0 scn
/GS0 gs
104.13 82.75 407.5 -10.83 re
f*
0.5 w
104.13 82.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
75 0 obj
<>
endobj
91 0 obj
<>
endobj
44 0 obj
<>
endobj
38 0 obj
<>
endobj
36 0 obj
<>
endobj
69 0 obj
<>stream
HV lT=gl0clOb&x8 f +H@
))VB (BlK$D@=lD:wo
j Y|}YWRhPK'/
,QҾH sE
. bemW43ѯrt\|P#f) 7P,̓osl*We|&Us/nтl{ռ~xɄukr BtT*XPҲY(V|\;؋XhDwc!Ƣ=!+w Y؆
_*X8KQiN߿r2q3QB {8&>Uk-#=~ěÍ\Fo![͘QI^oO:h8xR]G,ш!Ic#y`(FGދlNrRoY/^qYyX4ᮘ$nf:`}G_
)=S0ȌiK" 1T=q@^ŭPv1ZWYgM:Y i53nMdoLG 1Yjg=72Ï}w;ήfBBe;>h$3(
OLS4Q.*\XWqԊfC4}⚸%n.3ٙ#{P)m ?[_)wìƷ2UT?WS\V٢lU)T)}@Vsbuz{
Rm굝Y힣tΕzl?{~ӞF,F|,H/.:+Lwj1I!ެ(;ǷNjB$(uk]
;H[huJb?)=GpU~LSyKO^=sgflZj7W.k q:>!}tm"#MU@4FmPxB7uFS,g`ݦkSoIL4~<1h`kgb53\IFQ /٣w~lJX:Œ5 WҖZ'
yt 0|S`*` S$XW`@Zjh4xZh8Rc~pmfd9S6ڐ;L2bt3B>(ź\vV5z0Y3"똞"Sm˞BRhm_X3"Oފ沰ݶ:KB[B#(ZIRhcފ:+@kG6OpQ_iK89M۟(!.$R\b<=ubȷS9I
=vEuVƺI{zu/ګ[8[PcԿϽ}{w }m$~ꖰ=-W!,rPcڎºIETC|{Qcyl'݃J&